Profile
SLGL VRTX REGN ALNY SGEN ARGX
Company Name Sol-Gel Technologies Ltd. Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. Seagen Inc. argenx SE
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $19.53M $117.98B $57.12B $43.28B $43.15B $34.40B
Employees 0.03K 6.10K 15.16K 2.23K 3.26K 1.60K
CEO Moshe Arkin Reshma Kewalramani FASN, Leonard S. Schleifer Yvonne L. Greenstreet David R. Epstein Timothy Van Hauwermeiren EMBA,
Ratings
SLGL VRTX REGN ALNY SGEN ARGX
Quant Rating Score 2 2 4 1 3 2
Quant Rating Sell Sell Buy Strong Sell Neutral Sell
Trading
SLGL VRTX REGN ALNY SGEN ARGX
Last Close $8.11 $479.53 $559.76 $322.64 $228.74 $563.31
High 52 $8.11 $516.74 $1201.76 $331.91 $228.74 $671.75
Low 52 $0.37 $396.64 $482.92 $224.58 $228.74 $461.01
Price vs. 52 Week High 0 % -7.2 % -53.42 % -2.79 % 0 % -16.14 %
Price vs. 52 Week Low 2091.89 % 20.9 % 15.91 % 43.66 % 0 % 22.19 %
Total Return
SLGL VRTX REGN ALNY SGEN ARGX
1 Month Return 15.86 % 5.99 % 7.88 % 8.11 % 0 % -2.03 %
3 Month Return 1786.05 % -0.97 % 1.01 % 35.69 % 0 % -3.03 %
6 Month Return 676.08 % 17.08 % -19.68 % 35.57 % 0 % -14.16 %
9 Month Return 1092.65 % -0.45 % -44.89 % 13.48 % 0 % 4.96 %
YTD Return 771.95 % 19.08 % -21.42 % 37.11 % 0 % -8.4 %
1 Year Return 831.65 % -2.56 % -48.18 % 23.61 % 0 % 22 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
SLGL VRTX REGN ALNY SGEN ARGX
Dividend Yield Percentage (TTM) - - 0.33 % - - -
Dividend Paid and Capex Coverage Ration (TTM) - -3.53 % 3.85 % -1.49 % -5.87 % -44.32 %
Dividend Per Share (TTM) - - 1.76 % - - -
Payout Ratio (TTM) - - 2.08 % - - -
Profitability
SLGL VRTX REGN ALNY SGEN ARGX
Gross Profit Margin TTM 77.56 % 86.03 % 84.94 % 86.01 % 79.1 % 46.33 %
Return on Assets TTM -48.2 % -4.32 % 11.98 % -6.4 % -16.61 % 13.45 %
Return on Equity TTM -43.98 % -6.25 % 14.77 % -509.33 % -20.8 % 16.83 %
Return on Capital Employed TTM 16.75 % -3.89 % 11.35 % -3.68 % -21.46 % -0.5 %
Net Income Per EBT TTM 100 % 329.41 % 90.27 % 75.89 % 101.33 % 25990.14 %
EBT Per Ebit TTM -346.36 % 40.44 % 129.3 % 308.03 % 98.26 % -11.64 %
EBIT Per Revenue TTM 31.12 % -6.69 % 27.37 % -4.91 % -31.24 % -1.24 %
Cash Flow To Debt Ratio TTM - -59.44 % 146.15 % -3.47 % -1043.73 % -201.37 %
Receivables Turnover TTM 3.12 6.15 2.53 5.62 3.91 2.46
Payables Turnover TTM 6.2 3.49 3.01 3.37 1.97 2.39
Inventory Turnover TTM - 1.14 0.66 5.01 0.96 2.93
Fixed Asset Turnover TTM 798.88 % 421.34 % 300.07 % 337.41 % 665.41 % 4929.48 %
Asset Turnover TTM 44.72 % 48.51 % 37.52 % 55.72 % 53.41 % 35.83 %
Operating Cash Flow Per Share TTM - -3.82 37.05 -0.35 -2.46 -1.07
Free Cash Flow Per Share TTM - -4.9 28.3 -0.58 -2.88 -1.09
Cash Per Share TTM 606.73 % 2413.86 % 7825.12 % 2024.29 % 939.52 % 4688.94 %
Operating Cash Flow Sales Ratio TTM - -8.83 % 28.06 % -1.92 % -23.12 % -3.54 %
Free Cash Flow Operating Cash Flow Ratio TTM - 128.33 % 76.4 % 167.11 % 117.04 % 102.26 %
Cash Flow Coverage Ratios TTM - -59.44 % 146.15 % -3.47 % -1043.73 % -201.37 %
Price To Free Cash Flows Ratio TTM - -93.78 18.91 -574.08 -81.26 -443.33
Price To Operating Cash Flows Ratio TTM - -120.39 14.52 -954.11 -93.1 -526.76
Price Cash Flow Ratio TTM - -120.39 14.52 -954.11 -93.1 -526.76
Income Statement (TTM)
SLGL VRTX REGN ALNY SGEN ARGX
Revenue $0.01B $11.02B $14.2B $2.25B $1.96B $2.19B
Gross Profit $0.01B $9.49B $12.23B $1.92B $1.55B $1.96B
Gross Profit Ratio 97.98% 86.11% 86.13% 85.62% 79.1% 89.62%
EBITDA $-0.01B $0.49B $5.32B $-0.18B $-0.62B $0.11B
Net Income $-0.01B $-0.54B $4.41B $-0.28B $-0.61B $0.83B
EPS Diluted -0.38 -2.08 38.34 -2.16 -3.3 12.78
Balance Sheet (MRQ)
SLGL VRTX REGN ALNY SGEN ARGX
Long Term Debt $0B $1.66B $1.98B $0B $0.04B $0.03B
Total Liabilities $0.01B $6.12B $8.41B $4.17B $0.87B $0.7B
Total Equity $0.03B $16.41B $29.35B $0.07B $2.8B $5.5B
Total Investments $0.01B $6.65B $15.42B $1.73B $1.42B $1.93B
Total Debt $0B $1.75B $2.7B $1.3B $0.04B $0.04B
Total Assets $0.04B $22.53B $37.76B $4.3B $3.67B $6.2B
Cash Flow Statement (TTM)
SLGL VRTX REGN ALNY SGEN ARGX
Net Income $-0.01B $-0.54B $4.41B $-0.28B $-0.61B $-0.02B
Inventory $0B $-0.52B $-0.62B $0.01B $-0.23B $-0.09B
Dividends Paid $0B $0B $0B $0B $0B $0B
Operating Cash Flow $-0.01B $-0.49B $4.42B $-0.01B $-0.45B $-0.08B
Capital Expenditure $-0B $-0.3B $-0.76B $-0.03B $-0.08B $-0.07B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 38.24
AARD Aardvark Therapeutics, Inc. Common Stock 12.17
ABCL AbCellera Biologics Inc. 4.01
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.74
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 1.4
ABPWW 0.0351
ABSI Absci Corporation 2.67
ABUS Arbutus Biopharma Corporation 3.17
ABVC ABVC BioPharma, Inc. 3.97
ABVX Abivax SA American Depositary Shares 8.27
ACAD ACADIA Pharmaceuticals Inc. 20.98
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 0.7495
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 1.48
ACHV Achieve Life Sciences, Inc. 2.32
ACIU AC Immune SA 2.04
ETFs With Exposure to SLGL
Ticker ETF Name Weight Percentage Price
RYJ Invesco Raymond James SB-1 Equity ETF 0.019 65.3643
Unlock